References
- Hanaizi Z , van Zwieten-BootB, CalvoGet al. The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: summary of the scientific assessment of the Committee for Medicinal Products for Human Use. Eur. J. Cancer 48 (20), 237 – 242 (2012).
- Harbst K , StaafJ, LaussMet al. Molecular profiling reveals low- and high-grade forms of primary melanoma. Clin. Cancer Res. 18 (15), 4026 – 4036 (2012).
- Jonsson G , BuschC, KnappskogSet al. Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome. Clin. Cancer Res. 16 (13), 3356 – 3367 (2010).
- Eggermont AMM , SuciuS, RutkowskiPet al. Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized Phase III trial. J. Clin. Oncol. 31 (30), 3831 – 3837 (2013).
- Neuss H , KoplinG, RaueWet al. Analysing the serum levels of tumour markers and primary tumour data in stage III melanoma patients in correlation to the extent of lymph node metastases – a prospective study in 231 patients. Acta Chir. Belg. 111 (4), 214 – 8 (2011).
- Neagu M , ConstantinC, ZuracS. Immune parameters in prognosis and therapy monitoring of cutaneous melanoma patients – experience, role and limitations, Biomed. Res. Int. 2013, 107940 (2013).
- Domnanich P , SauerU, PultarJ, PreiningerC. Protein microarray for the analysis of human melanoma biomarkers.Sens. Actuators B Chem.139 (1), 2 – 8 (2009).